<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00856323</url>
  </required_header>
  <id_info>
    <org_study_id>702632</org_study_id>
    <nct_id>NCT00856323</nct_id>
  </id_info>
  <brief_title>Contingency Management for Methamphetamine Abstinence and HIV Post-Exposure Prophylaxis in Men Who Have Sex With Men</brief_title>
  <official_title>Biobehavioral Interventions for HIV-negative Methamphetamine-using MSM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Friends Research Institute, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Friends Research Institute, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to decrease methamphetamine use and concomitant high-risk sexual behaviors
      among methamphetamine-using men who have sex with men (MSM) by combining a biomedical
      intervention with a behavioral intervention. The behavioral intervention will consist of an
      8-week course of contingency management (CM) through which participants will be reinforced
      for testing negative for methamphetamine metabolites during periodic urine analyses. The
      biomedical intervention involves a 28-day course of an antiretroviral drug (Truvada) to be
      administered after an unanticipated HIV risk exposure (i.e., engaging in either receptive or
      insertive anal sex without a condom with someone who is HIV-positive or of unknown status).
      In combining these two interventions, this study seeks to evaluate the combined
      intervention's effects on sexual risk behaviors and methamphetamine use.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At the baseline, all eligible participants underwent informed consent; completed baseline
      assessments; received rapid HIV testing; provided specimens for syphilis, gonorrhea and
      chlamydia testing; and received a medical examination. Those who reported a high-risk sexual
      or drug exposure episode with an HIV-positive or serostatus-unknown source within the
      preceding 72 hours immediately initiated postexposure prophylaxis. All other participants
      received a 4-day ''starter pack'' of Truvada to be initiated only in the case of a future
      high-risk exposure to HIV. All participants began the voucher-based CM intervention upon
      study entry. For the initial 8 weeks of study conduct, participants presented to the study
      site three times weekly for a urine drug screen for methamphetamine metabolites. Participants
      who provided urine samples that were negative for methamphetamine metabolites earned
      vouchers, which escalated in value for successive negative urine samples. A participant with
      a missing sample or a sample positive for methamphetamine metabolites did not earn vouchers.
      Accrued vouchers were never forfeited and could be redeemed at any time during the study for
      gift certificates or goods or services that promote healthy, pro-social behaviors; vouchers
      could not be redeemed for cash.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Self-reported Methamphetamine Use in Previous 30 Days.</measure>
    <time_frame>3-months after baseline</time_frame>
    <description>Mean number of days (of the past 30) of methamphetamine use.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Description of Incident STI Infections.</measure>
    <time_frame>Baseline and 3-months</time_frame>
    <description>Proportional 3-month incidence of syphilis, rectal gonorrhea, pharyngeal gonorrhea, and rectal Chlamydia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-related Sexual Risk Behaviors in Previous 30 Days.</measure>
    <time_frame>3-months after baseline</time_frame>
    <description>Self-reported episodes of Unprotected Anal Intercourse in the previous 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-Exposure Prophylaxis Medication Adherence</measure>
    <time_frame>28-days</time_frame>
    <description>Median medication adherence rate, defined as the proportion of pills taken relative to the number of pills prescribed (i.e., # of pills taken / # of pills prescribed).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Amphetamine-Related Disorders</condition>
  <condition>HIV</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>PEP/CM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are provided contingency management vouchers for methamphetamine abstinence, and can initiate postexposure prophylaxis (Truvada; 1 pill daily for 28 days) after non-occupational exposure to HIV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Truvada</intervention_name>
    <description>At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).</description>
    <arm_group_label>PEP/CM</arm_group_label>
    <other_name>Emtricitabine and tenofovir disoproxil fumarate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>CM</intervention_name>
    <description>Participants will submit a urine sample every Monday, Wednesday, and Friday for 8 weeks (a total of 24 urine samples). Samples will be tested for methamphetamine metabolites.</description>
    <arm_group_label>PEP/CM</arm_group_label>
    <other_name>Contingency Management</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individual must identify as a male who has sex with other men (MSM);

          -  At least 18 years of age;

          -  HIV negative serostatus on baseline rapid oral HIV antibody test;

          -  Self-reported methamphetamine use within the previous 72 hours and test positive for
             methamphetamine metabolites at baseline;

          -  Self-reported unprotected anal intercourse (either receptive or insertive) with an
             HIV-positive or status unknown partner within the previous 3 months;

          -  Self-reports no previous hypersensitivity to any of the components of Truvada
             (tenofovir disoproxil fumarate or emtricitabine);

          -  Willing to comply with study requirements (i.e., monitored urine testing three times
             per week, meet with physician within first week of enrollment, begin medication
             immediately following an unexpected high-risk sexual exposure, and contact the clinic
             and meet with physician within 92 hours of unexpected high-risk sexual exposure).

        Exclusion Criteria:

          -  Does not identify as a male who has sex with other men;

          -  Under 18 years of age;

          -  HIV positive, by self-report or as indicated by the results on the baseline rapid oral
             HIV antibody test;

          -  Self-reports any previous hypersensitivity to any of the components of Truvada;

          -  Has not used methamphetamine in the previous 72 hours and does not test positive for
             methamphetamine metabolites;

          -  Has not had unprotected anal intercourse with an HIV-positive or status unknown
             partner within the previous 3 months;

          -  Unwilling to comply with study requirements.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cathy J Reback, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Friends Research Institute, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raphael J Landovitz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA Center for Clinical AIDS Research and Education</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steve Shoptaw, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA Department of Family Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Friends Community Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Landovitz RJ, Fletcher JB, Inzhakova G, Lake JE, Shoptaw S, Reback CJ. A novel combination HIV prevention strategy: post-exposure prophylaxis with contingency management for substance abuse treatment among methamphetamine-using men who have sex with men. AIDS Patient Care STDS. 2012 Jun;26(6):320-8. doi: 10.1089/apc.2011.0432.</citation>
    <PMID>22680280</PMID>
  </results_reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2009</study_first_submitted>
  <study_first_submitted_qc>March 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2009</study_first_posted>
  <results_first_submitted>August 27, 2012</results_first_submitted>
  <results_first_submitted_qc>October 26, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 27, 2012</results_first_posted>
  <last_update_submitted>August 12, 2016</last_update_submitted>
  <last_update_submitted_qc>August 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Methamphetamine</keyword>
  <keyword>HIV</keyword>
  <keyword>Post-exposure prophylaxis</keyword>
  <keyword>HIV seronegativity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Amphetamine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Methamphetamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between March 2009 and August 2010, 358 individuals inquired about the study on the basis of recruitment efforts, 64 presented for screening, and 53 participants enrolled in the study.</recruitment_details>
      <pre_assignment_details>Reasons for Screen Failure (N = 7): HIV-positive at baseline screening; negative urine screen for methamphetamineÂ§; did not complete baseline assessments; provided incorrect information at phone screening.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PEP/CM</title>
          <description>Truvada : At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).
CM : Participants will submit a urine sample every Monday, Wednesday, and Friday for 8 weeks (a total of 24 urine samples). Samples will be tested for methamphetamine metabolites.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PEP/CM</title>
          <description>Truvada : At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).
CM : Participants will submit a urine sample every Monday, Wednesday, and Friday for 8 weeks (a total of 24 urine samples). Samples will be tested for methamphetamine metabolites.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.1" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Self-reported Methamphetamine Use in Previous 30 Days.</title>
        <description>Mean number of days (of the past 30) of methamphetamine use.</description>
        <time_frame>3-months after baseline</time_frame>
        <population>53 enrolled and 2 were withdrawn.</population>
        <group_list>
          <group group_id="O1">
            <title>PEP/CM</title>
            <description>Truvada : At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).
CM : Participants will submit a urine sample every Monday, Wednesday, and Friday for 8 weeks (a total of 24 urine samples). Samples will be tested for methamphetamine metabolites.</description>
          </group>
        </group_list>
        <measure>
          <title>Self-reported Methamphetamine Use in Previous 30 Days.</title>
          <description>Mean number of days (of the past 30) of methamphetamine use.</description>
          <population>53 enrolled and 2 were withdrawn.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Description of Incident STI Infections.</title>
        <description>Proportional 3-month incidence of syphilis, rectal gonorrhea, pharyngeal gonorrhea, and rectal Chlamydia.</description>
        <time_frame>Baseline and 3-months</time_frame>
        <population>53 enrolled and 2 were withdrawn.</population>
        <group_list>
          <group group_id="O1">
            <title>PEP/CM</title>
            <description>Truvada : At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).
CM : Participants will submit a urine sample every Monday, Wednesday, and Friday for 8 weeks (a total of 24 urine samples). Samples will be tested for methamphetamine metabolites.</description>
          </group>
        </group_list>
        <measure>
          <title>Description of Incident STI Infections.</title>
          <description>Proportional 3-month incidence of syphilis, rectal gonorrhea, pharyngeal gonorrhea, and rectal Chlamydia.</description>
          <population>53 enrolled and 2 were withdrawn.</population>
          <units>Proportion of Participants</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".074" lower_limit=".045" upper_limit=".114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV-related Sexual Risk Behaviors in Previous 30 Days.</title>
        <description>Self-reported episodes of Unprotected Anal Intercourse in the previous 30 days.</description>
        <time_frame>3-months after baseline</time_frame>
        <population>53 enrolled and 2 were withdrawn.</population>
        <group_list>
          <group group_id="O1">
            <title>PEP/CM</title>
            <description>Truvada : At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).
CM : Participants will submit a urine sample every Monday, Wednesday, and Friday for 8 weeks (a total of 24 urine samples). Samples will be tested for methamphetamine metabolites.</description>
          </group>
        </group_list>
        <measure>
          <title>HIV-related Sexual Risk Behaviors in Previous 30 Days.</title>
          <description>Self-reported episodes of Unprotected Anal Intercourse in the previous 30 days.</description>
          <population>53 enrolled and 2 were withdrawn.</population>
          <units>episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".44" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-Exposure Prophylaxis Medication Adherence</title>
        <description>Median medication adherence rate, defined as the proportion of pills taken relative to the number of pills prescribed (i.e., # of pills taken / # of pills prescribed).</description>
        <time_frame>28-days</time_frame>
        <population>35 participants initiated PEP</population>
        <group_list>
          <group group_id="O1">
            <title>PEP/CM</title>
            <description>Truvada : At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).
CM : Participants will submit a urine sample every Monday, Wednesday, and Friday for 8 weeks (a total of 24 urine samples). Samples will be tested for methamphetamine metabolites.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-Exposure Prophylaxis Medication Adherence</title>
          <description>Median medication adherence rate, defined as the proportion of pills taken relative to the number of pills prescribed (i.e., # of pills taken / # of pills prescribed).</description>
          <population>35 participants initiated PEP</population>
          <units>proportional medication adherence</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" lower_limit="0.57" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PEP/CM</title>
          <description>Truvada : At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).
CM : Participants will submit a urine sample every Monday, Wednesday, and Friday for 8 weeks (a total of 24 urine samples). Samples will be tested for methamphetamine metabolites.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>shortness of breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Cathy Reback</name_or_title>
      <organization>Friends Research Institute, Inc.</organization>
      <phone>323-463-1601</phone>
      <email>reback@friendsresearch.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

